$TECH — WATCHLIST 📊

$TECH — WATCHLIST 📊 Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and biopro 🎯 Q2 2026 | Rev $0B | EPS $0.53 vs $0.53 ➖ 💡 None. Consensus EPS estimate was 0.53, actual 0.53—market is unlikely to reprice based on this event. Variant view: the market may be underestimating duration of stretched valuation and lack of growth drivers, but no upside gap exists. 📉 Reward/risk: 0:1 🏢 Business Quality: 5 — no evidence of durable competitive advantage or above-sector growth; quant rank 0th percentile suggests weak fundamentals relative to peers./10 📊 Valuation: rich — relative to health care peers on EV/EBITDA, P/B, P/E, and P/S. P/S >80x, P/E ~27.8x on normalized EPS. 🔮 Catalyst: none identified 📊 Our read: WATCHLIST. Full analysis → https://stockduty.xyz/s/TECH0625 Also in play: $AAPL $GOOGL $MSFT $AMZN $META $TSM

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and biopro